-
Mashup Score: 0What Matters to Patients: Metabolic Health Beyond Weight Loss - 8 month(s) ago
Radcliffe Medical Education bring together a distinguished panel of globally renowned experts who provide guidance on navigating the ever-changing landscape of obesity and metabolic
Source: www.radcliffecardiology.comCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 0Connecting with members at European Congress on Obesity 2023 | World Obesity Federation - 9 month(s) ago
ECO2023 delivered leading research and knowledge from experts over the course of four days in May.
Source: World Obesity FederationCategories: Endocrinology, Latest HeadlinesTweet-
The 2023 European Congress on Obesity (ECO) saw our members displaying leading research and learning from other experts over four days in Dublin, Ireland. #ECO2023 ➡️ Find out more: https://t.co/eWcHugpxOP https://t.co/qkNNHjMFOk
-
-
Mashup Score: 0
Adults with obesity who used semaglutide for weight loss reduced their 10-year risk for atherosclerotic cardiovascular disease, according to findings presented at the European Congress on Obesity. “This study is of immense clinical significance as we show that semaglutide (Wegovy, Novo Nordisk) is reducing one of the most common reasons of death, particularly in a population with obesity
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
#ICYMI: “We expected this improvement of #CVD risk after seeing the significant metabolic and BP improvements associated with #semaglutide." #ECO2023 @Wissam_Ghusn @MayoClinicGIHep @dr_aac @MayoClinic @EASOobesity https://t.co/0Q30UN0iuU
-
-
Mashup Score: 0
Adults with obesity who used semaglutide for weight loss reduced their 10-year risk for atherosclerotic cardiovascular disease, according to findings presented at the European Congress on Obesity. “This study is of immense clinical significance as we show that semaglutide (Wegovy, Novo Nordisk) is reducing one of the most common reasons of death, particularly in a population with obesity
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
#ICYMI: “This study is of immense clinical significance as we show that #semaglutide is reducing one of the most common reasons of death." #ECO2023 @Wissam_Ghusn @MayoClinicGIHep @dr_aac @MayoClinic @EASOobesity https://t.co/0Q30UN0iuU
-
-
Mashup Score: 0
Adults with obesity who used semaglutide for weight loss reduced their 10-year risk for atherosclerotic cardiovascular disease, according to findings presented at the European Congress on Obesity. “This study is of immense clinical significance as we show that semaglutide (Wegovy, Novo Nordisk) is reducing one of the most common reasons of death, particularly in a population with obesity
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
#Semaglutide may reduce the 10-year risk for ASCVD among adults with #obesity, according to findings presented at #ECO2023. @Wissam_Ghusn @MayoClinicGIHep @dr_aac @MayoClinic @EASOobesity https://t.co/0Q30UN0iuU
-
-
Mashup Score: 0Semaglutide linked to significant weight loss in adults with obesity in real-world study - 11 month(s) ago
Adults with overweight or obesity receiving semaglutide lost 13.4% of their body weight at 1 year, according to findings from a real-world study presented at the European Congress on Obesity. As Healio previously reported, an earlier study found adults receiving semaglutide (Wegovy, Novo Nordisk) in a real-world setting lost 10.9% of their body weight at 6 months. In new real-world data that
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
#ICYMI: “We also demonstrated similar improvement of most metabolic data [with #semaglutide], which would reflect a #CVD risk improvement.” @Wissam_Ghusn @MayoClinicGIHep @dr_aac @MayoClinic @EASOobesity #ECO2023 https://t.co/ARkBOk2mSD
-
-
Mashup Score: 0Semaglutide linked to significant weight loss in adults with obesity in real-world study - 11 month(s) ago
Adults with overweight or obesity receiving semaglutide lost 13.4% of their body weight at 1 year, according to findings from a real-world study presented at the European Congress on Obesity. As Healio previously reported, an earlier study found adults receiving semaglutide (Wegovy, Novo Nordisk) in a real-world setting lost 10.9% of their body weight at 6 months. In new real-world data that
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
#ICYMI: "In a first multicentered real-world study assessing the weight loss and metabolic outcomes of #semaglutide, we demonstrated effective weight-loss outcomes." @Wissam_Ghusn @MayoClinicGIHep @dr_aac @MayoClinic @EASOobesity #ECO2023 https://t.co/ARkBOk2mSD
-
-
Mashup Score: 4Semaglutide linked to significant weight loss in adults with obesity in real-world study - 11 month(s) ago
Adults with overweight or obesity receiving semaglutide lost 13.4% of their body weight at 1 year, according to findings from a real-world study presented at the European Congress on Obesity. As Healio previously reported, an earlier study found adults receiving semaglutide (Wegovy, Novo Nordisk) in a real-world setting lost 10.9% of their body weight at 6 months. In new real-world data that
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
In an analysis of real-world data, adults with overweight or #obesity lost 13.4% of their body weight after 1 year of receiving once-weekly #semaglutide. @Wissam_Ghusn @MayoClinicGIHep @dr_aac @MayoClinic @EASOobesity #ECO2023 https://t.co/gc3p7cEwLS
-
-
Mashup Score: 0Connecting with members at European Congress on Obesity 2023 | World Obesity Federation - 11 month(s) ago
ECO2023 delivered leading research and knowledge from experts over the course of four days in May.
Source: World Obesity FederationCategories: Endocrinology, Latest HeadlinesTweet-
The 2023 European Congress on Obesity (ECO) saw our members displaying leading research and learning from other experts over four days in Dublin, Ireland. #ECO2023 ➡️ Find out more: https://t.co/eWcHugpxOP https://t.co/kZXsVffuOx
-
-
Mashup Score: 3Gut Bacteria in Toddlers Predictive of Later Weight Gain - 11 month(s) ago
Gut microbiota at age 3.5 years is linked to increased BMI at 5 years, and the type and diversity of bacterial species are reflective of the microbiota of adults with obesity.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
A study presented at #ECO2023 suggests that gut microbiota in 3.5-year-old children is linked to higher BMI at age 5. BMI changes between ages 2 and 5 mirror those observed in adults with #obesity. https://t.co/zn3R9PAGEx
-
Explore leading experts guiding the dynamic world of #ObesityManagement & #MetabolicHealth. Discover unmet needs, patient outcomes, clinical data, and more. Empower your decisions and shape future care. 👉 https://t.co/4R5tweSZgl #ECO2023 #ECORME EASO 23 IME Symposium: What… https://t.co/epDQ7J7RBU https://t.co/gHHI59IAfM